Praxis Precision Medicines Quarterly Balance Sheets Chart
Quarterly
|
Annual
Praxis Precision Medicines Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||
| current assets: | ||||||||||||||||||||
| cash and cash equivalents | 157,415,000 | 165,567,000 | 215,372,000 | 168,645,000 | 145,143,000 | 151,980,000 | 81,300,000 | 101,085,000 | 124,300,000 | 80,839,000 | 61,615,000 | 62,440,000 | 56,039,000 | 77,854,000 | 138,704,000 | 165,679,000 | 175,879,000 | 131,152,000 | 296,608,000 | 114,772,000 |
| marketable securities | 143,860,000 | 162,424,000 | 177,195,000 | 188,387,000 | 206,736,000 | 55,436,000 | 4,983,000 | 38,874,000 | 61,300,000 | 109,365,000 | 144,662,000 | 137,207,000 | 148,691,000 | 163,305,000 | 139,659,000 | |||||
| prepaid expenses and other current assets | 5,304,000 | 5,584,000 | 11,805,000 | 3,016,000 | 4,837,000 | 4,388,000 | 3,580,000 | 2,242,000 | 5,529,000 | 8,580,000 | 10,351,000 | 8,572,000 | 10,176,000 | 11,957,000 | 11,498,000 | 4,969,000 | 9,249,000 | 7,753,000 | 5,718,000 | 1,079,000 |
| total current assets | 306,579,000 | 333,575,000 | 404,372,000 | 360,048,000 | 356,716,000 | 211,804,000 | 84,880,000 | 103,327,000 | 129,829,000 | 94,402,000 | 110,840,000 | 132,312,000 | 175,580,000 | 234,473,000 | 287,409,000 | 319,339,000 | 348,433,000 | 278,564,000 | 302,326,000 | 115,851,000 |
| long-term marketable securities | 145,369,000 | 144,032,000 | 76,961,000 | 54,141,000 | 81,952,000 | 35,873,000 | ||||||||||||||
| property and equipment | 258,000 | 247,000 | 230,000 | 277,000 | 369,000 | 476,000 | 588,000 | 700,000 | 759,000 | 865,000 | 971,000 | 1,077,000 | 1,134,000 | 1,142,000 | 1,213,000 | 625,000 | 182,000 | 109,000 | 82,000 | 98,000 |
| operating lease right-of-use assets | 626,000 | 882,000 | 1,131,000 | 1,374,000 | 1,610,000 | 1,840,000 | 2,064,000 | 2,282,000 | 2,494,000 | 2,700,000 | 2,901,000 | 3,097,000 | 3,287,000 | 3,473,000 | 3,653,000 | 4,028,000 | 4,400,000 | 571,000 | 754,000 | 933,000 |
| other non-current assets | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 416,000 | 472,000 | 416,000 | 496,000 | 9,000 | 15,000 | |||
| total assets | 452,832,000 | 478,736,000 | 483,110,000 | 416,256,000 | 441,063,000 | 250,409,000 | 87,948,000 | 106,725,000 | 133,498,000 | 98,383,000 | 115,128,000 | 136,902,000 | 180,417,000 | 239,504,000 | 292,747,000 | 324,408,000 | 353,511,000 | 279,253,000 | 303,177,000 | 119,548,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||
| accounts payable | 28,832,000 | 22,909,000 | 12,528,000 | 15,010,000 | 8,195,000 | 9,404,000 | 5,815,000 | 7,166,000 | 8,010,000 | 16,986,000 | 14,672,000 | 10,122,000 | 11,821,000 | 13,269,000 | 10,780,000 | 7,544,000 | 7,401,000 | 5,774,000 | 4,088,000 | 3,452,000 |
| accrued expenses | 19,021,000 | 15,547,000 | 23,763,000 | 15,457,000 | 10,058,000 | 6,976,000 | 7,416,000 | 6,979,000 | 13,317,000 | 9,352,000 | 15,850,000 | 17,884,000 | 25,768,000 | 30,929,000 | 26,844,000 | 16,529,000 | 7,826,000 | 7,386,000 | 10,869,000 | 6,186,000 |
| operating lease liabilities | 755,000 | 1,066,000 | 1,259,000 | 1,224,000 | 1,191,000 | 1,158,000 | 1,126,000 | 1,095,000 | 1,064,000 | 1,035,000 | 1,005,000 | 977,000 | 949,000 | 1,025,000 | 810,000 | 681,000 | 553,000 | 578,000 | 763,000 | 746,000 |
| total current liabilities | 48,608,000 | 39,522,000 | 37,550,000 | 32,861,000 | 20,620,000 | 18,794,000 | 15,749,000 | 16,792,000 | 24,430,000 | 29,916,000 | 34,345,000 | 28,983,000 | 38,538,000 | 45,223,000 | 38,434,000 | 24,754,000 | 15,780,000 | 13,738,000 | 15,720,000 | 10,384,000 |
| long-term liabilities: | ||||||||||||||||||||
| non-current portion of operating lease liabilities | 110,000 | 436,000 | 755,000 | 1,066,000 | 1,369,000 | 1,661,000 | 1,946,000 | 2,225,000 | 2,495,000 | 2,756,000 | 3,010,000 | 3,259,000 | 3,501,000 | 3,732,000 | 3,959,000 | 198,000 | ||||
| total liabilities | 48,608,000 | 39,522,000 | 37,660,000 | 33,590,000 | 21,963,000 | 20,726,000 | 18,279,000 | 19,969,000 | 27,873,000 | 33,915,000 | 39,022,000 | 31,739,000 | 41,548,000 | 48,482,000 | 41,935,000 | 28,486,000 | 19,739,000 | 13,738,000 | 15,720,000 | 10,582,000 |
| commitments and contingencies | ||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of june 30, 2025 and december 31, 2024 | ||||||||||||||||||||
| common stock | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 13,000 | 13,000 | 13,000 | 13,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 1,000 |
| additional paid-in capital | 1,380,978,000 | 1,344,577,000 | 1,281,522,000 | 1,159,382,000 | 1,145,308,000 | 923,141,000 | 723,577,000 | 713,786,000 | 708,023,000 | 632,580,000 | 606,918,000 | 595,165,000 | 585,070,000 | 576,955,000 | 567,598,000 | 553,975,000 | 547,145,000 | 442,524,000 | 437,007,000 | |
| accumulated other comprehensive gain | 395,000 | 659,000 | 654,000 | 1,331,000 | ||||||||||||||||
| accumulated deficit | -977,163,000 | -906,036,000 | -836,740,000 | -778,061,000 | -726,151,000 | -693,474,000 | -653,921,000 | -627,043,000 | -602,411,000 | -568,099,000 | -530,644,000 | -489,471,000 | -445,526,000 | -385,332,000 | -316,615,000 | -258,033,000 | -213,328,000 | -176,927,000 | -149,554,000 | -123,264,000 |
| total stockholders’ equity | 404,224,000 | 439,214,000 | 445,450,000 | 382,666,000 | 419,100,000 | 229,683,000 | 69,669,000 | 86,756,000 | 105,625,000 | 64,468,000 | 76,106,000 | 105,163,000 | 138,869,000 | 191,022,000 | 250,812,000 | 295,922,000 | 333,772,000 | 265,515,000 | 287,457,000 | |
| total liabilities and stockholders’ equity | 452,832,000 | 478,736,000 | 483,110,000 | 416,256,000 | 441,063,000 | 250,409,000 | 87,948,000 | 106,725,000 | 133,498,000 | 98,383,000 | 115,128,000 | 136,902,000 | 180,417,000 | 239,504,000 | 292,747,000 | 324,408,000 | 353,511,000 | 279,253,000 | ||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of march 31, 2025 and december 31, 2024 | ||||||||||||||||||||
| current portion of deferred revenue | 1,170,000 | 1,176,000 | 1,256,000 | 1,392,000 | 1,552,000 | 2,039,000 | 2,543,000 | 2,818,000 | ||||||||||||
| non-current portion of deferred revenue | 293,000 | 588,000 | 866,000 | 1,161,000 | 1,516,000 | 1,497,000 | 1,774,000 | 2,182,000 | ||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of december 31, 2024 and december 31, 2023 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of september 30, 2024 and december 31, 2023 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of june 30, 2024 and december 31, 2023 | ||||||||||||||||||||
| accumulated other comprehensive loss | -71,000 | -19,000 | -173,000 | -536,000 | -680,000 | -606,000 | -176,000 | -25,000 | -50,000 | -86,000 | ||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of march 31, 2024 and december 31, 2023 | ||||||||||||||||||||
| accumulated other comprehensive income | 3,000 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of december 31, 2023 and december 31, 20221 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of september 30, 2023 and december 31, 2022 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of june 30, 2023 and december 31, 2022 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of march 31, 2023 and december 31, 2022 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of december 31, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of september 30, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of june 30, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of march 31, 2022 and december 31, 2021 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of december 31, 2021 and december 31, 2020 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of september 30, 2021 and december 31, 2020 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of june 30, 2021 and december 31, 2020 | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of march 31, 2021 and december 31, 2020 | ||||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ (deficit) equity | ||||||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value; 8,075,799 shares authorized and 8,075,799 shares issued and outstanding as of december 31, 2019; liquidation value of 9,932 as of december 31, 2019 | ||||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value; 14,913,704 shares authorized and 14,913,704 shares issued and outstanding as of december 31, 2019; liquidation value of 49,969 as of december 31, 2019 | ||||||||||||||||||||
| series b-1 redeemable convertible preferred stock, 0.0001 par value; 2,666,666 shares authorized and 2,666,666 shares issued and outstanding as of december 31, 2019; liquidation value of 10,431 as of december 31, 2019 | ||||||||||||||||||||
| series c redeemable convertible preferred stock, 0.0001 par value; 11,067,963 shares authorized and 9,805,827 shares issued and outstanding as of december 31, 2019; liquidation value of 50,789 as of december 31, 2019 | ||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of december 31, 2020 | ||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ equity | 303,177,000 | |||||||||||||||||||
| restricted cash | 600,000 | |||||||||||||||||||
| other assets | 2,066,000 | |||||||||||||||||||
| liabilities, redeemable convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||
| series a redeemable convertible preferred stock, 0.0001 par value; 8,075,799 shares authorized as of september 30, 2020 and december 31, 2019; 8,075,799 shares issued and outstanding as of september 30, 2020 and december 31, 2019; liquidation value as of september 30, 2020 and december 31, 2019 of 10,416 and 9,932, respectively | 10,416,000 | |||||||||||||||||||
| series b redeemable convertible preferred stock, 0.0001 par value; 14,913,704 shares authorized as of september 30, 2020 and december 31, 2019; 14,913,704 shares issued and outstanding as of september 30, 2020 and december 31, 2019; liquidation value as of september 30, 2020 and december 31, 2019 of 52,648 and 49,969, respectively | 52,648,000 | |||||||||||||||||||
| series b-1 redeemable convertible preferred stock, 0.0001 par value; 2,666,666 shares authorized as of september 30, 2020 and december 31, 2019; 2,666,666 shares issued and outstanding as of september 30, 2020 and december 31, 2019; liquidation value as of september 30, 2020 and december 31, 2019 of 11,029 and 10,431, respectively | 11,029,000 | |||||||||||||||||||
| series c redeemable convertible preferred stock, 0.0001 par value; 8,543,692 shares authorized as of september 30, 2020 and 11,067,963 shares authorized as of december 31, 2019; 8,543,692 shares issued and outstanding as of september 30, 2020 and 9,805,827 shares issued and outstanding as of december 31, 2019; liquidation value as of september 30, 2020 and december 31, 2019 of 46,244 and 50,789, respectively | 46,244,000 | |||||||||||||||||||
| series c-1 redeemable convertible preferred stock, 0.0001 par value; 19,444,453 shares authorized as of september 30, 2020 and no shares authorized as of december 31, 2019; 19,444,453 shares issued and outstanding as of september 30, 2020 and no shares issued and outstanding as of december 31, 2019; liquidation value as of september 30, 2020 and december 31, 2019 of 111,892 and 0, respectively | 111,892,000 | |||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||
| total stockholders’ deficit | -123,263,000 | |||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders’ deficit | 119,548,000 | |||||||||||||||||||
| operating expenses: | ||||||||||||||||||||
| research and development | 12,786,000 | |||||||||||||||||||
| general and administrative | 3,431,000 | |||||||||||||||||||
| total operating expenses | 16,217,000 | |||||||||||||||||||
| income from operations | -16,217,000 | |||||||||||||||||||
| other income: | ||||||||||||||||||||
| interest income | 1,000 | |||||||||||||||||||
| total other income | 1,000 | |||||||||||||||||||
| income before benefit from income taxes | -16,216,000 | |||||||||||||||||||
| benefit from income taxes | ||||||||||||||||||||
| net income and comprehensive loss | -16,216,000 | |||||||||||||||||||
| accretion and cumulative dividends on redeemable convertible preferred stock | -3,943,000 | |||||||||||||||||||
| gain on repurchase of redeemable convertible preferred stock | ||||||||||||||||||||
| net income attributable to common stockholders | -20,159,000 | |||||||||||||||||||
| net income per share | -12,100 | |||||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 1,665,902,000 |
We provide you with 20 years of balance sheets for Praxis Precision Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Praxis Precision Medicines. Explore the full financial landscape of Praxis Precision Medicines stock with our expertly curated balance sheets.
The information provided in this report about Praxis Precision Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.